Transplant Genomics

Transplant Genomics is a molecular diagnostics company specializing in non-invasive serial monitoring guided by genomics. It offers TruGraf, a blood-based test to rule out silent subclinical rejection in stable kidney transplant recipients. The company also provides diagnostic and predictive tests for kidney and liver graft dysfunction.
TypeSubsidiary
Parent CompanyEurofins Scientific
HQMansfield, MA, US
Founded2013
Websitetrugraf.com
Cybersecurity ratingBMore
Transplant Genomics was founded in 2013 and is headquartered in Mansfield, MA, US

Viewing summary data as a guest

Sign up for free to see all data
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Transplant Genomics

Stanley Rose

Stanley Rose

President & CEO
Peter Meintjes

Peter Meintjes

Chief Commercial Officer
John Holman

John Holman

VP, Medical Affairs
Show more

Transplant Genomics Office Locations

Transplant Genomics has an office in Mansfield
Mansfield, MA, US (HQ)
905 S Main St #102
Show all (1)

Transplant Genomics Financials and Metrics

Summary Metrics

Founding Date

2013
Transplant Genomics is a subsidiary of Eurofins Scientific

Transplant Genomics Cybersecurity Score

Cybersecurity ratingPremium dataset

B

85/100

SecurityScorecard logo

Transplant Genomics Online and Social Media Presence

Embed Graph

Transplant Genomics News and Updates

Medivolve Signs Agreement With California Lab, Transplant Genomics, to Offer Free COVID-19 PCR Tests Through HRSA Program

As part of the Government funded HRSA program, Collection Sites will be able to offer uninsured and undocumented patients with access to free PCR tests. As part of the Government funded HRSA program, Collection Sites will be able to offer uninsured and undocumented patients with access to free PCR t…

Transplant Genomics Blogs

Combining Blood Gene Expression and Cellfree DNA to Diagnose Subclinical Rejection in Kidney Transplant Recipients

Clinical Journal of the American Society of Nephrology, October 2021, https://doi.org/10.2215/CJN.05530421 Sookhyeon Park, Kexin Guo, Raymond L. Heilman, Emilio D. Poggio, David J. Taber, Christopher L. Marsh, Sunil M. Kurian, Steve Kleiboeker, Juston Weems, John Holman, Lihui Zhao, Rohita Sinha, Su…

Eurofins Transplant Genomics Launches OmniGraf, the Only Combination Biomarker Panel that Provides the Earliest Indication of Rejection in Kidney Transplant Recipients

September 27, 2021 Provides significantly higher positive predictive value (PPV) and negative predictive value (NPV) than any other kidney rejection assays on the market. FRAMINGHAM, MA — Eurofins Transplant Genomics (“TGI”), the transplant rejection diagnostics company committed to improving organ …

Eurofins Transplant Genomics Announces 2021-2022 Scientific Advisory Board

Leading transplant surgeons, nephrologists, and scientists help guide Eurofins in the development of novel diagnostics to address unmet needs in transplantation with the goal of improving long-term outcomes. FRAMINGHAM, MA — Eurofins Transplant Genomics (“TGI”), the transplant rejection diagnostics …

Transplant Genomics Frequently Asked Questions

  • When was Transplant Genomics founded?

    Transplant Genomics was founded in 2013.

  • Who are Transplant Genomics key executives?

    Transplant Genomics's key executives are Stanley Rose, Peter Meintjes and John Holman.

  • How many employees does Transplant Genomics have?

    Transplant Genomics has 66 employees.

  • Who are Transplant Genomics competitors?

    Competitors of Transplant Genomics include Clongene, Ipsum Diagnostics and Moleculera Labs.

  • Where is Transplant Genomics headquarters?

    Transplant Genomics headquarters is located at 905 S Main St #102, Mansfield.

  • Where are Transplant Genomics offices?

    Transplant Genomics has an office in Mansfield.

  • How many offices does Transplant Genomics have?

    Transplant Genomics has 1 office.